E-Mail
Health Level Seven International (HL7®) and the Observational Health Data Sciences and Informatics (OHDSI) network announced a collaboration to address the sharing and tracking of data in the healthcare and research industries by creating a single common data model. The organizations will integrate HL7 Fast Healthcare Interoperability Resources (FHIR®) and OHDSI s Observational Medical Outcomes Partnership (OMOP) common data model to achieve this goal.
HL7 International CEO Dr. Charles Jaffe, M.D., Ph.D., underscored the significance of this partnership. The Covid-19 pandemic has emphasized the need to share global health and research data. He continued, Collaboration with OHDSI is critical to solving this challenge and will help our mutual vision of a world in which everyone can securely access and use the right data when and where they need it.
Two common blood pressure drugs are not tied to increased risk of COVID-19
Research published in the peer-reviewed journal
The Lancet Digital Health and co-led by a UCLA Fielding School of Public Health faculty member has found that two widely used types of blood pressure drugs are not tied to an increased risk of COVID-19 infection or complications.
The international team co-led by Dr. Marc Suchard, UCLA Fielding School professor of biostatistics, found that there was no increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications for users of either angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs). The study, the world s largest, examined a group of more than 1.1 million patients in the United States and Spain using antihypertensives, researchers said.
Patients on ACE inhibitors, ARBs, don t have higher COVID-19 risk medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
E-Mail
NEW YORK, NY (Dec. 17, 2020) While the COVID-19 pandemic left the world searching for answers during the earliest stages of the pandemic, one immediate healthcare concern regarded the use of certain antihypertensives and whether they posed increased risks to patients with hypertension.
A new study by global collaborators within the Observational Health Data Sciences and Informatics (OHDSI) community found that there was no increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications for users of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) among an international cohort of more than 1.1 million patients using antihypertensives.
The study was published today in